MedTrace Logo

Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH

NCT05162950 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-01-11

No results posted yet for this study

Summary

Individuals with CAH produce lower levels of epinephrine (adrenalin) than controls. This can be correlated to the CYP21A2 genotype and is most pronounced in the classic forms. Individuals with CAH have an increased risk of developing hypoglycemia because both cortisol and epinephrine are important counter regulatory hormones. Stress dosing is essential in situations of increased physical stress such as infections with fever for example.

Glucocorticoid treatment and stress dosing cannot compensate fully during physical stress neither for the reaction to psychological stress. This may render various types of difficulties in the individual's life.

We aim to investigate if the deficient epinephrine production can be confirmed and if it is related to the increased level of anxiety and vulnerability to stress that we observe in the patients.

Specific aims of the study:

* Analyse the epinephrine/adrenalin production in patients with CAH using measurements of epinephrine and metanephrine in blood, during an exercise test
* Assess stress vulnerability and anxiety using validated questionnaires
* Correlate the results to severity of disease, CYP21A2 genotype
* Investigate if psychological and somatic stress symptoms are related to the epinephrine production capacity.

Conditions

  • Congenital Adrenal Hyperplasia

Interventions

DIAGNOSTIC_TEST

physical exercise as a standardized high intensity exercise test

High intensity exercise test, cycling, performed at the Karolinska University Hospital

BEHAVIORAL

Stress vulnerability

Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire

Sponsors & Collaborators

  • Region Stockholm

    lead OTHER_GOV

Principal Investigators

  • Fredrika Gauffin, MDPhD · Karolinska University Hospital

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05162950 on ClinicalTrials.gov